Evidence map›Paper›PMID 35732692›Full record

ArticleMolecular psychiatry2023

The show must go on. Reply to "Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al" by Insop Shim.

Jordi Bonaventura, Sherry Lam, Meghan Carlton, Matthew Boehm, Juan L Gomez, Oscar Solís, Marta Sánchez-Soto, Patrick J Morris, Ida Fredriksson, Craig J Thomas and 4 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jordi BonaventuraDepartament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, L'Hospitalet de Llobregat, 08907, Catalonia, Spain. jbonaventura@ub.edu.ORCID 0000-0002-4745-0151
Sherry LamBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA.
Meghan CarltonBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA.
Matthew BoehmBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA.
Juan L GomezBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA.
Oscar SolísBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA.ORCID 0000-0002-8285-5891
Marta Sánchez-SotoMolecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, MD, 20892, USA.ORCID 0000-0003-3343-5628
Patrick J MorrisDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA.
Ida FredrikssonNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212245, USA.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville, MD, 20850, USA.
David R SibleyMolecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, MD, 20892, USA.ORCID 0000-0002-0624-962X
Yavin ShahamNeurobiology of Relapse Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212245, USA.ORCID 0000-0002-8242-3319
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Intramural Research Program, Bethesda, MD, 20892, USA.
Michael MichaelidesBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 212242, USA. mike.michaelides@nih.gov.ORCID 0000-0003-0398-4917

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Molecular And Pharmacological Studies Of Dopamine ReceptorsZIANS002263 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SIBLEY, DAVID · 2009 to 2025
$37.4M
Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse MechanismsZIADA000069 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI MICHAELIDES, MICHAEL · 2016 to 2025
$18.9M
Development of (R,R)-dehydronorketamine for treatment resistant depressionZIATR000042 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI THOMAS, CRAIG · 2015 to 2022
$18.5M
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2020-117989RA-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) RYC-2019-027371-IU.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) ZIA00069
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

KetamineSubstance-Related DisordersAnimalsExcitatory Amino Acid AntagonistsHumansEsketamineExcitatory Amino Acid AntagonistsKetamine

Identifiers

PMID35732692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.